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Cellular immunotherapy is a promising approach to spe-
cific treatment of cancer. Dendritic cells (DC) are the best-
studied antigen presenting cells (APC) and have been
tested in multiple clinical trials over the last years. To
extend this strategy to clinical situations in which DC ther-
apy might be more challenging, e.g. pediatric patients or
to approaches with frequent vaccinations, we have estab-
lished CD40-activated B cells (CD40-B cells) as a comple-
mentary autologous APC, due to the simple generation of
large amounts of highly efficient CD40-B cells from small
amounts of peripheral blood. Similar to the pharmaceuti-
cal development of DC to become a standardizable adju-
vant, several important biological aspects need to be
addressed for CD40-B cells prior to "product develop-
ment" according to GMP conditions.
We have identified efficient presentation of antigen in the
context of MHC class I and MHC class II as well as homing
capabilities to secondary lymphoid organs as essential
biological criteria for this cellular adjuvant to merit fur-
ther development. Recently, we showed that antigen-
loaded CD40-B cells expand memory and induce primary
CD8+ T cell responses in healthy donors and cancer
patients alike.
Here we address, whether CD40-B do process antigens in
the context of MHC class II and induce secondary as well
as primary CD4+ T-cell responses: We developed a T-cell
expansion system that uses CD40-B cells as sole APC to
induce antigen-specific responses of purified CD4+ T-cells:
1) tetanus toxoid (TT) and keyhole limpet hemocyanin
(KLH), were used as a model for whole protein antigens,
2) the artificial promiscuous MHC class II binding pep-
tides PADRE-AKF and PADRE-AKX served as model pep-
tide-neoantigens. After 2 to 5 rounds of stimulation with
antigen-loaded CD40-B cells ELISPOT technology was
used to determine the presence of antigen specific CD4+ T-
cells. While specific cells were successfully expanded for
all antigens studied, INF-γ and IL-4 cytokine secretion pro-
files did not indicate a dominant polarization towards
TH1 or TH2 lineage.
Similarly important, we addressed, if CD40-B cells have
the potential to home to lymph nodes and induce T-cell
chemotaxis: CD40-B lack receptors important for relocat-
ing to peripheral tissue but do express CD62L, LFA-1,
CCR7 and CXCR4, receptors implied in homing to sec-
ondary lymphoid organs. Migration experiments using
their cognate ligands CXCL12, CCL19 and CCL21 dem-
onstrated that these receptors are fully functional and
mediate migration of CD40-B cells. Furthermore, CD40-B
cells express several important T-cell attractants including
IP-10, Rantes, MCP-1 and ENA-78. Correspondingly
supernatant from CD40-B cultures induces strong chemo-
taxis of CD4+ and CD8+ T-cells.
Taken together, CD40-B cells efficiently induce primary
MHC class I and II restricted T-cell responses and have
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potential to home to secondary lymphoid organs. Based
on these findings pre-clinical models have been devel-
oped to assess the in vivo capacity of these cells to effi-
ciently migrate to T cell rich areas of secondary lymphoid
organs and to induce efficient T cell activation.Page 2 of 2
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